Modified stents for interventional therapy of peripheral arterial occlusive disease;Modifizierte stents für die interventionelle therapie der pAVK

Vasa - Journal of Vascular Diseases

Volumn 33, Issue SUPPL. 64, 2004, Pages 55-58

  Duda, Stephan ^a   Heller, Stefan ^a   Wiesinger, Benjamin ^a   Tepe, Gunnar ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; CARBON; DACTINOMYCIN; DEXAMETHASONE; ESTRADIOL; PACLITAXEL; RAPAMYCIN; TACROLIMUS;

ARTERY INTIMA PROLIFERATION; CLINICAL TRIAL; DRUG ELUTING STENT; HUMAN; INCIDENCE; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RESTENOSIS; REVIEW;

EID: 1542344883     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.33.s64.55     Document Type: Review

References (14)

1. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997; 96: 636-45.
2. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Thielemans H, Ziemer G, Cristea E, Lansky A, Beregi JP. Sirolimus-eluting Stents for the treatment of obstructive superficial femoral artery disease: six-months-result. Circulation.2002 Sep 17; 106 (12): 1505-9.
3. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496-501.
4. Haase J, Störger H, Hofmann M, Braun H, Schwarz C-E, Reinemer H, Schwarz F. Bewirkt die Beschichtung von koronaren Edelstahlstents mit turbostratischem Carbon eine Reduktion von klinischen Ereignissen und In-Stent-Restenosen? Ergebnisse einer prospektiven randomisierten Vergleichsstudie. Z Kardiol 2002; 91: Suppl I: 66.
5. Heldman AW, Cheng L, Jenkins M, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103: 2289-95.
6. Hoffmann R, Mintz GS. Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J 2000; 21: 1739-49.
7. Liistro F, Stankovic G, Di-Mario C, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 2002; 105: 1883-6.
8. Marx SO, Marks AR. The development of rapamycin and its application to stent restenosis. Circulation 2001; 104: 852-5.
9. Muller DW, Golomb G, Gordon D, et al. Site specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation. Coronary artery disease. 1994; 5: 435-42.
10. Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart 2002; 87: 305-7.
11. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of Sirolimus-eluting stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001; 103: 192-5.
12. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by Sirolimus-eluting stents: one-year angiographic and intravascular follow-up. Circulation. 2001; 104: 2007-11.
13. Strecker EP, Gabelmann A, Boos I, et al. Effect on intimal hyperplasia of dexamethasone released from eluting metal stents compared with non-eluting stents in canine femoral arteries. Cardiovasc Intervent Radiol. 1998; 21: 487-96.
14. Suzuki T, Kopia G, Hayashi S, et al. Stent based delivery of Sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104: 1188-93.